Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease

Annals of Neurology

Volumn 72, Issue 4, 2012, Pages 564-570

  Niedowicz, Dana M ^a   Beckett, Tina L ^a   Matveev, Sergey ^a   Weidner, Adam M ^a   Baig, Irfan ^a   Kryscio, Richard J ^a,b   Mendiondo, Marta S ^a,b   Levine, Harry ^a   Keller, Jeffrey N ^c   Murphy, M Paul ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DODECYL SULFATE SODIUM; OLIGOMER; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INFERIOR PARIETAL LOBULE; MALE; MIDDLE FRONTAL GYRUS; MIDDLE TEMPORAL GYRUS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; SUBICULUM; SUPERIOR TEMPORAL GYRUS;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; AUTOPSY; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; NEUROPSYCHOLOGICAL TESTS; PLAQUE, AMYLOID; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE-ACTIVE AGENTS; THIAZOLES;

EID: 84868117094     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23633     Document Type: Article

References (42)

1. Hardy J,. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110: 1129-1134.
2. Querfurth HW, LaFerla FM,. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
3. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18 (4 suppl): S1-S2.
4. Atwood CS, Martins RN, Smith MA, Perry G,. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002; 23: 1343-1350.
5. Haass C, Selkoe DJ,. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
6. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
7. Murphy MP, Beckett TL, Ding Q, et al. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 2007; 27: 301-311.
8. Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 2007; 66: 1136-1146.
9. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199.
10. Wang Y, Klunk WE, Debnath ML, et al. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci 2004; 24: 55-62.
11. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
12. Grimmer T, Henriksen G, Wester HJ, et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 2009; 30: 1902-1909.
13. Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010; 31: 1284-1303.
14. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4'- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-2092.
15. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-10606.
16. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-434.
17. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131 (pt 6): 1630-1645.
18. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2008; 65: 1304-1309.
19. Schmitt FA, Wetherby MM, Wekstein DR, et al. Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. Gerontologist 2001; 41: 716-722.
20. Nelson PT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010; 20: 66-79.
21. Schmitt FA, Davis DG, Wekstein DR, et al. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000; 55: 370-376.
22. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006; 63: 38-46.
23. Braak H, Braak E,. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
24. Beckett TL, Niedowicz DM, Studzinski CM, et al. Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol Dis 2010; 39: 449-456.
25. Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003; 23: 8532-8538.
26. McGowan E, Pickford F, Kim J, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005; 47: 191-199.
27. Weidner AM, Bradley MA, Beckett TL, et al. RNA oxidation adducts 8-OHG and 8-OHA change with Abeta(42) levels in late-stage Alzheimer's disease. PloS One 2011; 6: e24930.
28. Head E, Pop V, Sarsoza F, et al. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 2010; 20: 637-646.
29. LeVine H III,. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 2004; 335: 81-90.
30. Rosen RF, Walker LC, Levine H III,. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging 2011; 32: 223-234.
31. Holm S,. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
32. Thal DR, Rub U, Orantes M, Braak H,. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
33. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
34. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
35. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
36. McDonald JM, Savva GM, Brayne C, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133 (pt 5): 1328-1341.
37. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30: 1026-1036.
38. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
39. Walsh DM, Selkoe DJ,. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-193.
40. Sojkova J, Resnick SM,. In vivo human amyloid imaging. Curr Alzheimer Res 2011; 8: 366-372.
41. Svedberg MM, Hall H, Hellstrom-Lindahl E, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009; 54: 347-357.
42. Murphy MP, LeVine H III,. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010; 19: 311-323.